Carlock C, Bai Y, Paige-Hood A, Li Q, Nguele Meke F, Zhang Z
JCI Insight. 2023; 8(19).
PMID: 37665633
PMC: 10619439.
DOI: 10.1172/jci.insight.170065.
Park M
Int J Mol Sci. 2023; 24(15).
PMID: 37569414
PMC: 10418941.
DOI: 10.3390/ijms241512037.
Papa A, Pandolfi P
Curr Top Microbiol Immunol. 2022; 436:95-115.
PMID: 36243841
DOI: 10.1007/978-3-031-06566-8_4.
Ghoneum A, Said N
Cancers (Basel). 2019; 11(7).
PMID: 31284467
PMC: 6679095.
DOI: 10.3390/cancers11070949.
Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F
Cancers (Basel). 2019; 11(4).
PMID: 30925702
PMC: 6520939.
DOI: 10.3390/cancers11040435.
Targeting PDK1 for Chemosensitization of Cancer Cells.
Emmanouilidi A, Falasca M
Cancers (Basel). 2017; 9(10).
PMID: 29064423
PMC: 5664079.
DOI: 10.3390/cancers9100140.
Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes.
Cojohari O, Peppenelli M, Chan G
J Virol. 2016; 90(14):6443-6452.
PMID: 27147739
PMC: 4936122.
DOI: 10.1128/JVI.00214-16.
The Role of PTEN in Myeloid Malignancies.
Morotti A, Panuzzo C, Crivellaro S, Carra G, Torti D, Guerrasio A
Hematol Rep. 2016; 7(4):5844.
PMID: 26734127
PMC: 4691678.
DOI: 10.4081/hr.2015.6027.
Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.
Huang X, Li D, Li T, Zhao B, Chen X
Oncol Lett. 2015; 10(1):103-110.
PMID: 26170984
PMC: 4486892.
DOI: 10.3892/ol.2015.3189.
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.
Fransecky L, Mochmann L, Baldus C
Mol Cell Ther. 2015; 3:2.
PMID: 26056603
PMC: 4452048.
Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
Nishioka C, Ikezoe T, Yang J, Yokoyama A
PLoS One. 2015; 10(5):e0125017.
PMID: 25955299
PMC: 4425466.
DOI: 10.1371/journal.pone.0125017.
PTEN: Multiple Functions in Human Malignant Tumors.
Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N
Front Oncol. 2015; 5:24.
PMID: 25763354
PMC: 4329810.
DOI: 10.3389/fonc.2015.00024.
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhofer N, Metzeler K, Rothenberg M, Herold T, Tiedt S, Groiss V
Leukemia. 2014; 29(4):828-38.
PMID: 25322685
DOI: 10.1038/leu.2014.305.
Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T
Nat Commun. 2014; 5:3393.
PMID: 24569712
PMC: 3948061.
DOI: 10.1038/ncomms4393.
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis V
Mol Cell Biol. 2013; 33(16):3091-8.
PMID: 23732914
PMC: 3753920.
DOI: 10.1128/MCB.00319-13.
Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
Cesano A, Putta S, Rosen D, Cohen A, Gayko U, Mathi K
PLoS One. 2013; 8(2):e56714.
PMID: 23431389
PMC: 3576376.
DOI: 10.1371/journal.pone.0056714.
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
Martelli A, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D
Oncotarget. 2012; 3(4):371-94.
PMID: 22564882
PMC: 3380573.
DOI: 10.18632/oncotarget.477.
Functional analysis of the protein phosphatase activity of PTEN.
Zhang X, Piccini A, Myers M, Van Aelst L, Tonks N
Biochem J. 2012; 444(3):457-64.
PMID: 22413754
PMC: 3365644.
DOI: 10.1042/BJ20120098.
Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice.
Xiao Y, Guo Y, Breslin P, Zhang S, Wei W, Zhang Z
Leukemia. 2011; 25(12):1857-68.
PMID: 21926961
PMC: 3237817.
DOI: 10.1038/leu.2011.220.
Evi1 forms a bridge between the epigenetic machinery and signaling pathways.
Yoshimi A, Kurokawa M
Oncotarget. 2011; 2(7):575-86.
PMID: 21795762
PMC: 3248179.
DOI: 10.18632/oncotarget.304.